EIF4A3-induced circFAT1 promotes high glucose-induced podocyte damage via miR-30e-5p/SOX4 axis

Youqun Huang1,2, Yu Liu1, Mengfan Yang1

  • 1Department of Nephrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

RNA Biology
|October 20, 2025
PubMed

Insights

Circular RNA circFAT1 exacerbates diabetic nephropathy (DN) by promoting podocyte injury via the miR-30e-5p/SOX4 pathway. Inhibiting circFAT1 may offer a new therapeutic strategy for DN.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Nephrology

Background:

  • Podocyte injury is a key factor in diabetic nephropathy (DN) pathogenesis.
  • Circular RNAs (circRNAs) are increasingly recognized as critical regulators in disease processes.
  • circFAT1 (hsa_circ_0001461) has emerged as a potential player in pathological conditions.

Purpose of the Study:

  • To investigate the role of hsa_circ_0001461 in high glucose (HG)-induced podocyte damage.
  • To elucidate the underlying molecular mechanisms.
  • To assess the clinical relevance of circFAT1 in diabetic nephropathy patients.

Main Methods:

  • Studied circFAT1 expression in high glucose-induced podocyte injury models.
  • Investigated the effects of circFAT1 inhibition on podocyte migration and differentiation.
  • Utilized molecular techniques to explore the circFAT1/miR-30e-5p/SOX4 signaling pathway.
  • Analyzed circFAT1 levels in patient samples.

Main Results:

  • circFAT1 expression was significantly upregulated in podocytes under HG conditions.
  • Inhibition of circFAT1 reduced podocyte migration and reversed epithelial-mesenchymal transition markers.
  • circFAT1 was found to inhibit miR-30e-5p, leading to increased SOX4 expression.
  • Elevated circFAT1 levels in DN patients correlated with disease severity (albuminuria, serum creatinine).

Conclusions:

  • circFAT1 plays a critical role in high glucose-induced podocyte injury.
  • The mechanism involves the circFAT1/miR-30e-5p/SOX4 signaling pathway.
  • circFAT1 represents a potential therapeutic target for diabetic nephropathy intervention.